Management of Pulmonary Thromboembolism

Initial Management

The European Society of Cardiology recommends beginning anticoagulation immediately upon suspicion of PE while diagnostic workup proceeds, unless active bleeding or absolute contraindications exist 1, 2
Risk stratification based on hemodynamic stability is the critical first step that determines the entire treatment pathway, with high-risk PE characterized by cardiogenic shock and/or persistent arterial hypotension 2, 3, 4

For high-risk PE, the European Heart Journal recommends initiating intravenous unfractionated heparin immediately with a bolus of 5,000-10,000 units followed by continuous infusion, and administering systemic thrombolysis unless absolutely contraindicated 4, 2
The European Heart Journal suggests administering supplemental oxygen to correct hypoxemia, and correcting systemic hypotension with vasopressors to prevent right ventricular failure progression 4, 5
Surgical pulmonary embolectomy is the recommended alternative if thrombolysis fails or is contraindicated, with catheter-based embolectomy or fragmentation considered if surgery is unavailable 4, 5, 2

For hemodynamically stable patients, the European Heart Journal recommends initiating low-molecular-weight heparin or fondaparinux as the preferred initial anticoagulation over unfractionated heparin 4, 1, 2
The European Heart Journal suggests continuing initial anticoagulation for at least 5 days before transitioning to oral anticoagulation, with unfractionated heparin reserved for patients with severe renal dysfunction or high bleeding risk 4, 2

The European Heart Journal recommends transitioning to a direct oral anticoagulant rather than warfarin for long-term anticoagulation in eligible patients, with rivaroxaban, apixaban, dabigatran, and edoxaban as preferred options 1, 2, 6
The European Heart Journal suggests using vitamin K antagonists targeting INR 2.5 if direct oral anticoagulants are contraindicated, with overlap with parenteral anticoagulation until INR ≥2.0 for at least 2 consecutive days 4, 6

The European Heart Journal recommends that all patients require at least 3 months of therapeutic anticoagulation, with the decision to extend based on individual risk-benefit assessment 4, 1, 2, 6
The European Heart Journal suggests considering extended anticoagulation with reduced-dose rivaroxaban or apixaban to balance efficacy and bleeding risk 1

The European Heart Journal recommends using low-molecular-weight heparin over warfarin or direct oral anticoagulants for at least 6 months in cancer patients, with recent evidence suggesting edoxaban and rivaroxaban may be acceptable alternatives 4, 1
The European Heart Journal suggests using low-molecular-weight heparin as the anticoagulant of choice throughout pregnancy, with direct oral anticoagulants and warfarin contraindicated 1

The European Heart Journal recommends routinely re-evaluating all patients 3-6 months after acute PE, assessing for persistent dyspnea or functional limitation, evaluating bleeding complications, screening for occult malignancy, and deciding on anticoagulation duration based on risk-benefit assessment 1, 2, 6, 3